Literature DB >> 30328586

Dynamic Changes in the Estimated Glomerular Filtration Rate Predict All-Cause Mortality After Intravenous Thrombolysis in Stroke Patients.

Jijun Shi1, Yuanyuan Liu2,3, Yiteng Liu1, Huihui Liu1, Jiaping Xu1, Xia Zhang1, Shoujiang You1, Yongjun Cao4.   

Abstract

Little is known about the prognostic value of the estimated glomerular filtration rate (eGFR) and the effect of dynamic changes in the eGFR on mortality in acute ischemic stroke (AIS) patients treated with intravenous thrombolysis (IVT). We aim to investigate the association between the eGFR and dynamic changes in the eGFR after IVT with all-cause mortality in AIS patients. A total of 391 AIS patients treated with IVT between May 2010 and May 2017 were included in the final analysis. Serum creatinine was measured at admission and within 24 h after IVT. The main outcomes included 3-month all-cause mortality and major adverse cardiac and cerebrovascular events (MACCE). During the 3-month follow-up, 37 (9.5%) patients died from all causes. Mortality was associated with a reduced eGFR at admission (adjusted hazard ratio (HR), 4.17; 95% confidence interval (CI), 1.50-11.58; P trend = 0.016) and within 24 h after IVT (adjusted HR, 5.88; 95% CI, 1.41-24.52; P trend = 0.009). Mortality was negatively correlated with increased eGFR after IVT (adjusted HR, 0.70; 95% CI, 0.51-0.96; P trend = 0.027). Additionally, a reduced eGFR after IVT was also associated with increased risk of MACCE (adjusted HR, 3.64; 95% CI, 1.41-9.39; P trend = 0.009). Using a multivariable Cox regression model with restricted cubic splines, we observed an L-shaped association between the eGFR and 3-month all-cause mortality and MACCE and observed a linear association between dynamic changes in the eGFR and 3-month all-cause mortality. A reduced eGFR and dynamic decreases in the eGFR after IVT independently predict 3-month all-cause mortality in AIS patients.

Entities:  

Keywords:  Acute ischemic stroke; Estimated glomerular filtration rate; Intravenous thrombolysis; Mortality; Recombinant tissue plasminogen activator

Mesh:

Substances:

Year:  2018        PMID: 30328586     DOI: 10.1007/s12640-018-9970-7

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  35 in total

1.  Renal function and outcome among stroke patients treated with IV thrombolysis.

Authors:  P A Lyrer; F Fluri; D Gisler; S Papa; F Hatz; S T Engelter
Journal:  Neurology       Date:  2008-11-04       Impact factor: 9.910

2.  Serial decline of kidney function as a novel biomarker for the progression of atherothrombotic disease.

Authors:  Philipp Rein; Christoph H Saely; Axel Muendlein; Alexander Vonbank; Heinz Drexel
Journal:  Atherosclerosis       Date:  2010-03-01       Impact factor: 5.162

3.  GFR estimating equations in a multiethnic Asian population.

Authors:  Boon Wee Teo; Hui Xu; Danhua Wang; Jialiang Li; Arvind Kumar Sinha; Borys Shuter; Sunil Sethi; Evan J C Lee
Journal:  Am J Kidney Dis       Date:  2011-05-20       Impact factor: 8.860

4.  Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous rt-PA: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry.

Authors:  Masaki Naganuma; Masatoshi Koga; Yoshiaki Shiokawa; Jyoji Nakagawara; Eisuke Furui; Kazumi Kimura; Hiroshi Yamagami; Yasushi Okada; Yasuhiro Hasegawa; Kazuomi Kario; Satoshi Okuda; Kazutoshi Nishiyama; Kazuo Minematsu; Kazunori Toyoda
Journal:  Cerebrovasc Dis       Date:  2010-11-17       Impact factor: 2.762

5.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

6.  Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension.

Authors:  Thórdís Hrafnkelsdóttir; Pia Ottosson; Thorarinn Gudnason; Ola Samuelsson; Sverker Jern
Journal:  Hypertension       Date:  2004-07-12       Impact factor: 10.190

7.  Chronic kidney disease and clinical outcome in patients with acute stroke.

Authors:  Gilad Yahalom; Roseline Schwartz; Yvonne Schwammenthal; Oleg Merzeliak; Maya Toashi; David Orion; Ben-Ami Sela; David Tanne
Journal:  Stroke       Date:  2009-01-29       Impact factor: 7.914

8.  Fibrin clot structure in patients with end-stage renal disease.

Authors:  Jonas A Sjøland; Johannes J Sidelmann; Mikkel Brabrand; Robert S Pedersen; Jørgen H Pedersen; Kim Esbensen; Kristina F Standeven; Robert A S Ariëns; Jørgen Gram
Journal:  Thromb Haemost       Date:  2007-08       Impact factor: 5.249

9.  Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality.

Authors:  George Tsagalis; Theodore Akrivos; Maria Alevizaki; Efstathios Manios; Kimon Stamatellopoulos; Antonis Laggouranis; Konstantinos N Vemmos
Journal:  Nephrol Dial Transplant       Date:  2008-08-26       Impact factor: 5.992

10.  Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study.

Authors:  Emanuele Di Angelantonio; Rajiv Chowdhury; Nadeem Sarwar; Thor Aspelund; John Danesh; Vilmundur Gudnason
Journal:  BMJ       Date:  2010-09-30
View more
  2 in total

1.  Pooled incidence and case-fatality of acute stroke in Mainland China, Hong Kong, and Macao: A systematic review and meta-analysis.

Authors:  Fan He; Irene Blackberry; Liqing Yao; Haiyan Xie; Tshepo Rasekaba; George Mnatzaganian
Journal:  PLoS One       Date:  2022-06-27       Impact factor: 3.752

2.  Acute and Chronic Kidney Dysfunction and Outcome After Stroke Thrombectomy.

Authors:  Simon Fandler-Höfler; Balazs Odler; Markus Kneihsl; Gerit Wünsch; Melanie Haidegger; Birgit Poltrum; Markus Beitzke; Hannes Deutschmann; Christian Enzinger; Alexander R Rosenkranz; Thomas Gattringer
Journal:  Transl Stroke Res       Date:  2021-01-04       Impact factor: 6.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.